OFFICIAL PUBLICATION OF

by its subsidiary APPco

Baricitinib update

15/10/2021

New monograph released to guide safe treatment of serious COVID-19 symptoms The Society of Hospital Pharmacists of Australia has brought forward the release of streamlined information on the safe administration of baricitinib for people with severe COVID-19 symptoms requiring ventilation While baricitinib is approved for the treatment of active rheumatoid arthritis and atopic dermatitis, in

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Recent Comments
Popular Posts

Escape the city for better pay

If what Raven Recruitment claimed ($120k salary package for a pharmacist manager in a metropolitan area) is true, it is…

Morbidly Obese John

CAPS leaders to contest Guild elections

Just found it curious that the single Carrum Downs polling booth where CAPS were active had an 8% swing away…

Michael Khoo

Vyvanse supply issues ease

In general, around 3 months late in admitting there is a shortage, and at least one month too soon in…

Michael Khoo

Review backs same job, same pay

Genuine question. Are we offering the same service? I'm not sure how GPs claim from Medicare but if I see…

John Smith

Baricitinib update

Previous API acquisition joust not over yet

Next Guild partners for coal industry health

Clinical tips: Timing!

Clinical tips: Movement disorders

Clinical tips: Worms, Worms, Worms

Intranasal Midazolam for at home use

MENU

Previous API acquisition joust not over yet

Next Guild partners for coal industry health

Related Posts

MENU

Hi there! 👋 Looks like you’re not logged in.